New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Core Insights - Genentech, a member of the Roche Group, announced the publication of a detailed analysis of the Phase III ALLEGORY trial for Gazyva (obinutuzumab) in adults with systemic lupus erythematosus (SLE) in the New England Journal of Medicine [1] - The study showed a statistically significant and clinically meaningful benefit in the primary endpoint, with over three quarters (76.7%) of participants treated with Gazyva plus standard therapy achieving the primary endpoint [1] Company Summary - Gazyva is being evaluated for its effectiveness in treating systemic lupus erythematosus, a chronic autoimmune disease [1] - The publication in a prestigious journal like NEJM highlights the importance and credibility of the findings related to Gazyva [1] Industry Context - The results from the ALLEGORY trial may influence treatment protocols for systemic lupus erythematosus, potentially leading to increased adoption of Gazyva in clinical practice [1] - The positive outcomes from the trial could enhance the competitive positioning of Genentech and Roche in the autoimmune disease treatment market [1]